NCT04452214 - A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | Crick

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria (Part 1): * Subjects with metastatic or locally advanced, incurable non-small-cell lung cancer (NSCLC \[adenocarcinoma, adenosquamous, or squamous\]), head and neck squamous cell carcinoma (HNSCC), urothelial cancer, or malignant melanoma who have exhausted or declined available standard therapy. * Subjects progressing on previous treatment with a checkpoint inhibitor targeting thePD-1/PD-L1 pathway, alone or in combination with chemotherapy after previously having achieved stable disease or better and stayed on such therapy for ≥12 weeks. * Primary or metastatic lesion suitable for biopsy and willingness to undergo repeat biopsies as appropriate. * Willing and able to provide intravenous access for the administration of the study drug and for blood sampling/testing. Inclusion Criteria (Part 2): * Subjects with histologically confirmed non-squamous metastatic (stage IV) NSCLC, without option for locoregional treatment with curative intent. * Subjects who have not received prior systemic anti-cancer therapy for the locally advanced or metastatic NSCLC. Subjects who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of metastatic disease. * Ability to safety undergo pre-treatment (if no archival biopsy is available) and on-treatment tumor biopsies. * Subject consents to retrieval of archival tumor tissue for screening in case no fresh biopsy is performed during screening. * Willing and able to provide intravenous access for the administration of the study drug and for blood sampling/testing. Exclusion Criteria (Parts 1 and 2): * Subjects with NSCLC tumors with genetic alteration or mutation, for which FDA-approved targeted therapy is available. * Treatment with systemic anticancer treatments, investigational products, or major surgery within 4 weeks before first dose of study drug or 5 half-lives, whichever is shorter. Subjects should have recovered from previous treatment toxicity (except hair loss and peripheral neuropathy). * History of uncontrolled brain metastasis. * Subject has received extended field radiotherapy ≤4 weeks before the start of treatment (≤2 weeks for limited field radiation to alleviate symptoms), and who has not recovered from related side effects of such therapy (except for hair loss). * Subjects who have previously experienced an immune-related adverse event (irAE) to pembrolizumab, for which permanent discontinuation is required. Subjects without a formal contraindication due to previous irAE are not eligible if the AE has not resolved or requires steroids (\>10 mg prednisone-equivalent per day) for ongoing management. * Subjects with active severe infection requiring oral antibiotics. * Clinical evidence of an active second invasive malignancy with the exception of stable prostate cancer on watchful waiting. * Uncontrolled or significant cardiovascular disease. * History of autoimmune disease requiring systemic immunosuppressive therapy (daily prednisone equivalent doses \>10 mg/day). * HIV patients can be enrolled if the infection is adequately controlled. * Known bleeding disorder or coagulopathy. Subjects on stable anticoagulant therapy are allowed. * Known or suspected allergy to study treatment or related products. * Women who are pregnant or breastfeeding, or trying to become pregnant. * Patients with chronic viral hepatitis. Exclusion criteria (Part 2): * Previous therapy with immunotherapy (anti-PD-1, anti-PD-L1, and anti-PD-L2, anti-CTLA-4, or other approved or investigational checkpoint-inhibitors). * Subject is unable or unwilling to take folic acid or vitamin B12 supplementation. * Subject is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDS), other than an aspirin dose ≤ 1.3 g per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam). Other protocol-defined inclusion/exclusion criteria may apply.